{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:07:49Z","timestamp":1778684869359,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005624","name":"Medizinischen Hochschule Hannover","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00908-0","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:25:36Z","timestamp":1773062736000},"page":"1121-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent Immunological and Neurotrophic Responses to CD20 Depletion in Relapsing and Progressive Multiple Sclerosis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1919-0070","authenticated-orcid":false,"given":"Gudrun M.","family":"K\u00f6rner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-3515","authenticated-orcid":false,"given":"Thiemo M.","family":"M\u00f6llenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin F.","family":"Jendretzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3985-1246","authenticated-orcid":false,"given":"Julian R.","family":"Kretschmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Christina Saparilla","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janna M.","family":"Siemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarle","family":"von H\u00f6rsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-5674","authenticated-orcid":false,"given":"Franz F.","family":"Konen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin W.","family":"H\u00fcmmert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1031-9966","authenticated-orcid":false,"given":"Franziska","family":"Bachhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1647-6201","authenticated-orcid":false,"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2942-7924","authenticated-orcid":false,"given":"Roland","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-335X","authenticated-orcid":false,"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5695","authenticated-orcid":false,"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"2","key":"908_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169\u201380.","journal-title":"N Engl J Med"},{"issue":"10422","key":"908_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, et al. Multiple sclerosis. Lancet. 2024;403(10422):183\u2013202.","journal-title":"Lancet"},{"issue":"2","key":"908_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-0036-1579739","volume":"36","author":"M Sospedra","year":"2016","unstructured":"Sospedra M, Martin R. Immunology of multiple sclerosis. Semin Neurol. 2016;36(2):115\u201327.","journal-title":"Semin Neurol"},{"issue":"1","key":"908_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27\u201340.","journal-title":"Eur J Neurol"},{"key":"908_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116.","journal-title":"Front Immunol"},{"issue":"11","key":"908_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41573-024-01026-y","volume":"23","author":"B Becher","year":"2024","unstructured":"Becher B, Derfuss T, Liblau R. Targeting cytokine networks in neuroinflammatory diseases. Nat Rev Drug Discov. 2024;23(11):862\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"908_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neuroscience.2024.04.004","volume":"548","author":"Z Khan","year":"2024","unstructured":"Khan Z, Mehan S, Gupta GD, Narula AS. Immune system dysregulation in the progression of multiple sclerosis: molecular insights and therapeutic implications. Neuroscience. 2024;548:9\u201326.","journal-title":"Neuroscience"},{"issue":"1","key":"908_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-024-01077-7","volume":"17","author":"R Amoriello","year":"2024","unstructured":"Amoriello R, Memo C, Ballerini L, Ballerini C. The brain cytokine orchestra in multiple sclerosis: from neuroinflammation to synaptopathology. Mol Brain. 2024;17(1):4.","journal-title":"Mol Brain"},{"issue":"3","key":"908_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/sclerosis2030012","volume":"2","author":"C Toftegaard","year":"2024","unstructured":"Toftegaard C, Severinsen CM, Jensen HB. Biomarkers differentiating RRMS and SPMS in multiple sclerosis\u2014a systematic review. Sclerosis. 2024;2(3):166\u201385.","journal-title":"Sclerosis"},{"issue":"3","key":"908_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"908_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med"},{"key":"908_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010012","author":"S Gingele","year":"2018","unstructured":"Gingele S, Jacobus TL, Konen FF, Hummert MW, Suhs KW, Schwenkenbecher P, et al. Ocrelizumab depletes CD20(+) T cells in multiple sclerosis patients. Cells. 2018. https:\/\/doi.org\/10.3390\/cells8010012.","journal-title":"Cells"},{"issue":"3","key":"908_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/cei\/uxac090","volume":"210","author":"NM de Gruijter","year":"2022","unstructured":"de Gruijter NM, Jebson B, Rosser EC. Cytokine production by human B cells: role in health and autoimmune disease. Clin Exp Immunol. 2022;210(3):253\u201362.","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"908_CR14","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/art.24998","volume":"60","author":"E Wilk","year":"2009","unstructured":"Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009;60(12):3563\u201371.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"908_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"2","key":"908_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"key":"908_CR17","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2021","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021."},{"key":"908_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H. ggplot2: Elegant graphics for data analysis. 2nd ed. Cham, Switzerland: Springer International Publishing; 2016.","edition":"2"},{"key":"908_CR19","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran\u00e7ois R, et al. Welcome to the tidyverse. J Open Source Softw. 2019. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"J Open Source Softw"},{"issue":"9","key":"908_CR20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, Havrdova E. \u201cNo evident disease activity\u201d: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23(9):1179\u201387.","journal-title":"Mult Scler"},{"issue":"4","key":"908_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200427","volume":"12","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or A, Nicholas J, Feng J, Sorrell F, Cascione M. Exploring the clinical utility of neurofilament light chain assays in multiple sclerosis management. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200427.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"17","key":"908_CR22","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1289\/ehp.7199","volume":"112","author":"JH Lubin","year":"2004","unstructured":"Lubin JH, Colt JS, Camann D, Davis S, Cerhan JR, Severson RK, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect. 2004;112(17):1691\u20136.","journal-title":"Environ Health Perspect"},{"issue":"6","key":"908_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.17219\/acem\/68846","volume":"27","author":"OM Koper","year":"2018","unstructured":"Koper OM, Kaminska J, Sawicki K, Kemona H. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. Adv Clin Exp Med. 2018;27(6):849\u201356.","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"908_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0022-510X(01)00680-3","volume":"195","author":"E Scarpini","year":"2002","unstructured":"Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, Conti G, et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci. 2002;195(1):41\u20136.","journal-title":"J Neurol Sci"},{"issue":"3","key":"908_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11011-020-00648-6","volume":"36","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, Honarmand K, Taheri M. A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis. Metab Brain Dis. 2021;36(3):375\u2013406.","journal-title":"Metab Brain Dis"},{"issue":"1","key":"908_CR26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4049\/jimmunol.160.1.444","volume":"160","author":"WE Biddison","year":"1998","unstructured":"Biddison WE, Cruikshank WW, Center DM, Pelfrey CM, Taub DD, Turner RV. CD8+ myelin peptide-specific T cells can chemoattract CD4+ myelin peptide-specific T cells: importance of IFN-inducible protein 10. J Immunol. 1998;160(1):444\u20138.","journal-title":"J Immunol"},{"issue":"1-2","key":"908_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0165-5728(98)00053-8","volume":"87","author":"K Hohnoki","year":"1998","unstructured":"Hohnoki K, Inoue A, Koh CS. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha\/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol. 1998;87(1\u20132):27\u201332.","journal-title":"J Neuroimmunol"},{"issue":"23","key":"908_CR28","doi-asserted-by":"publisher","first-page":"12952","DOI":"10.1073\/pnas.1912839117","volume":"117","author":"J Huang","year":"2020","unstructured":"Huang J, Khademi M, Fugger L, Lindhe O, Novakova L, Axelsson M, et al. Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proc Natl Acad Sci U S A. 2020;117(23):12952\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"908_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1239","volume":"2","author":"OA Haabeth","year":"2011","unstructured":"Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240.","journal-title":"Nat Commun"},{"issue":"Pt 1","key":"908_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/brain\/awf015","volume":"125","author":"C Stadelmann","year":"2002","unstructured":"Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. 2002;125(Pt 1):75\u201385.","journal-title":"Brain"},{"key":"908_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103984","volume":"65","author":"N Karimi","year":"2022","unstructured":"Karimi N, Ashourizadeh H, Akbarzadeh Pasha B, Haghshomar M, Jouzdani T, Shobeiri P, et al. Blood levels of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (MS): a systematic review and meta-analysis. Mult Scler Relat Disord. 2022;65:103984.","journal-title":"Mult Scler Relat Disord"},{"issue":"Pt 8","key":"908_CR32","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/brain\/awq176","volume":"133","author":"JL Jones","year":"2010","unstructured":"Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133(Pt 8):2232\u201347.","journal-title":"Brain"},{"issue":"1-2","key":"908_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jneuroim.2005.07.001","volume":"167","author":"D Azoulay","year":"2005","unstructured":"Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol. 2005;167(1\u20132):215\u20138.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"908_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000515595","volume":"28","author":"M Shajarian","year":"2021","unstructured":"Shajarian M, Alsahebfosoul F, Etemadifar M. The effect of IFN-beta treatment on plasma levels of BDNF and IL-6 in relapsing-remitting multiple sclerosis patients. NeuroImmunoModulation. 2021;28(3):150\u20137.","journal-title":"NeuroImmunoModulation"},{"key":"908_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-021-00296-2","author":"MI Oraby","year":"2021","unstructured":"Oraby MI, El Masry HA, Abd El Shafy SS, Abdul Galil EM. Serum level of brain-derived neurotrophic factor in patients with relapsing-remitting multiple sclerosis: a potential biomarker for disease activity. Egypt J Neurol Psychiatr Neurosurg. 2021. https:\/\/doi.org\/10.1186\/s41983-021-00296-2.","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"908_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.107096","volume":"215","author":"LJ Schroder","year":"2025","unstructured":"Schroder LJ, Konen FF, Thiesler H, Gudi V, Hildebrandt H, Schwenkenbecher P, et al. Altered microglial polarization reduces demyelination in cerebellar slices treated with serum from CD20-depleted multiple sclerosis patients. Neurobiol Dis. 2025;215:107096.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"908_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1034\/j.1600-0404.2001.00356.x","volume":"104","author":"J Losy","year":"2001","unstructured":"Losy J, Niezgoda A. IL-18 in patients with multiple sclerosis. Acta Neurol Scand. 2001;104(3):171\u20133.","journal-title":"Acta Neurol Scand"},{"issue":"1-2","key":"908_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jneuroim.2011.12.008","volume":"243","author":"YC Chen","year":"2012","unstructured":"Chen YC, Chen SD, Miao L, Liu ZG, Li W, Zhao ZX, et al. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol. 2012;243(1\u20132):56\u201360.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"908_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1084\/jem.20141015","volume":"212","author":"JM Rumble","year":"2015","unstructured":"Rumble JM, Huber AK, Krishnamoorthy G, Srinivasan A, Giles DA, Zhang X, et al. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med. 2015;212(1):23\u201335.","journal-title":"J Exp Med"},{"key":"908_CR40","unstructured":"Gross CC, Schulte-Mecklenbeck A, Steinberg OV, Wirth T, Lauks S, Bittner S, et al. Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories. Sci Transl Med. 2024;16(740):eade8560."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00908-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:07:59Z","timestamp":1778681279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00908-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00908-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest regarding this publication. Outside the submitted work, the authors received honoraria for lectures, consulting, travel grants or research grants. Thiemo M. M\u00f6llenkamp received travel honoraria from Merck Healthcare and Novartis. Konstantin F. Jendretzky received travel compensation and congress fee from Merck, Neuraxpharm, Argenx and Novartis. Julian R. Kretschmer received institutional research support from NEMOS e.V. Franz F. Konen received honoraria for lectures and travel compensation from Alexion, Argenx, Merck, Novartis, Siemens and Takeda, research support as fellow of the German Research Foundation and Hannover Medical School-funded Clinician Scientist Program and from Merck, Siemens and Erwin-R\u00f6ver-Foundation. Martin W. H\u00fcmmert received research support from Myelitis e. V., German Federal Joint Committee\/Innovation Fund, NEMOS e.V. and Argenx, speaker honoraria from selpers og, AMGEN\/Horizon and Alexion, travel grants from Alexion and compensation for serving on advisory boards from Alexion, Roche, AMGEN and UCB. Hayrettin Tumani received institutional support for research projects from Ministry of Science and Arts State BW, BG, DMSG and Chemische Fabrik Karl Bucher GmbH, and he received honoraria for acting as a consultant\/speaker and\/or for attending events sponsored by Alexion, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Diamed, Fresenius, Fujirebio, GlaxoSmithKline, Hexal, Horizon, Janssen-Cilag, Merck, Novartis, Ottobock, Roche, Sanofi-Genzyme, Siemens, Teva and Viatris. Hayrettin Tumani is a member of the following societies: AMSEL, DGG, DGLN, DGN, DMSG, EAN, GENERATE, GBS and NEMOS.\u00a0Thomas Skripuletz reports research support from Alnylam, CSL Behring, Merck, Novartis and Siemens; honoraria for lectures, travel support and\/or consultancy fees from Alexion, Alnylam, Amgen, argenx, Bayer, Biogen, Bristol Myers Squibb, Centogene, CSL Behring, Grifols, Hexal AG, Horizon, Janssen, Merck, Novartis, Pfizer, Purpose pharma, Roche, Sanofi, Siemens, SOBI, Teva and Viatris. Stefan Gingele reports research support from Alnylam Pharmaceuticals, CSL Behring, Else Kr\u00f6ner Fresenius Foundation, Deutsche Forschungsgemeinschaft and Hannover Biomedical Research School and consulting and\/or speaker honoraria or compensation for travel or congress fees from Alexion, Alnylam Pharmaceuticals, AstraZeneca, CSL Behring, GSK, Pfizer, Merck and Takeda Pharmaceuticals all outside the submitted work. Gudrun M. K\u00f6rner, Anna Christina Saparilla Pietschmann, Janna M. Siemer, Jarle von H\u00f6rsten, Philipp Schwenkenbecher, Franziska Bachhuber and Roland Jacobs report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All research procedures were in concordance with the Helsinki Declaration of 1964 and its later amendments to ensure full compliance with ethical guidelines. The study was approved by the local Ethics Committee of Hannover Medical School (no. 8787_BO_K_2019), and the included patients gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}